Opinion

Video

The DORA Trial

Panelists discuss how the phase 3 DORA trial investigates the combination of standard of care darolutamide with radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), building upon the positive safety profile of novel hormone therapy combinations with radiopharmaceuticals seen in PEACE-3.

Video content above is prompted by the following:

  • Can you discuss the ongoing phase 3 DORA trial?
Related Videos
1 expert in this video
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.